药捷安康-B(02617):替恩戈替尼片新药上市申请获国家药品监督管理局受理

Core Viewpoint - The new drug application for Tienogratinib tablets has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, aimed at treating adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received at least one systemic therapy and FGFR inhibitor treatment [1] Group 1 - Tienogratinib tablets are intended for patients with advanced cholangiocarcinoma [1] - The drug has previously been included in the priority review and breakthrough therapy lists [1]